Prostacyclin in liver disease: a potential therapeutic option

Bibliography

• HAUSSINGER D, KUBITZ R, REINEHR R, BODE JG, SCHLIESS F: Molecular aspects of medicine: from experimental to clinical hepatology. Mol. Aspects Med. (2004) 25(3):221-360.
   PubMedGoogle Scholar
• BILZER M, ROGGEL F, GERBES AL: Role of Kupffer cells in host defense and liver disease. Liver Int. (2006) 26(10):1175-1186.
   PubMed Web of Science ®Google Scholar
• JARVELAINEN HA, FANG C, INGELMAN-SUNDBERG M, LINDROS KO: Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. Hepatology (1999) 29(5):1503-1510.
   PubMed Web of Science ®Google Scholar
• MATHURIN P, DENG QG, KESHAVARZIAN A et al.: Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology (2000)32(5):1008-1017.
   PubMed Web of Science ®Google Scholar
• DAI LL, GONG JP, ZUO GQ et al.: Synthesis of endotoxin receptor CD14 protein in Kupffer cells and its role in alcohol-induced liver disease.World J. Gastroenterol. (2003) 9(3):622-626.
   PubMed Web of Science ®Google Scholar
• McCLAIN CJ, COHEN DA: Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology (1989) 9(3):349-351.
   PubMed Web of Science ®Google Scholar
• MOOKERJEE RP, SEN S, DAVIES NA et al.: Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. GUT (2003) 52(8):1182-1187.
   PubMed Web of Science ®Google Scholar
• TILG H, KASER A, MOSCHEN AR: How to modulate inflammatory cytokines in liver diseases. Liver Int. (2006) 26(9):1029-1039.
   PubMed Web of Science ®Google Scholar
• PALEKAR NA, NAUS R, LARSON SP, WARD J, HARRISON SA: Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. (2006) 26(2):151-156.
   PubMed Web of Science ®Google Scholar
• HAUKELAND JW, DAMAS JK, KONOPSKI Z et al.: Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. (2006) 44(6):1167-74.
   PubMed Web of Science ®Google Scholar
• SCHATTENBERG JM, GALLE PR, SCHUCHMANN M: Apoptosis in liver disease. Liver Int. (2006) 26(8):904-911.
   PubMed Web of Science ®Google Scholar
• BACHEM MG, SELL KM, MELCHIOR R et al.: Tumor necrosis factor alpha (TNF alpha) and transforming growth factor beta 1 (TGF beta 1) stimulate fibronectin synthesis and the transdifferentiation of fat-storing cells in the rat liver into myofibroblasts. Virchows Arch. B Cell. Pathol. Incl. Mol. Pathol. (1993) 63(2):123-130.
   PubMedGoogle Scholar
• NAPOLI J, BISHOP GA, MCGUINNESS PH, PAINTER DM, MCCAUGHAN GW: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology (1996) 24(4):759-765.
   PubMed Web of Science ®Google Scholar
• WEDEMEYER H, HE XS, NASCIMBENI M et al.: Impaired effector function of hepatitis C virus-specific CD8(+) T cells in chronic hepatitis C virus infection. J. Immunol. (2002) 169(6):3447-3458.
   PubMed Web of Science ®Google Scholar
• MAINI MK, BONI C, LEE CK et al.: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. (2000) 191(8):1269-1280.
   PubMed Web of Science ®Google Scholar
• THIMME R, WIELAND S, STEIGER C et al.: CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. (2003) 77(1):68-76.
   PubMed Web of Science ®Google Scholar
• WEBSTER GJ, REIGNAT S, BROWN D et al.: Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. (2004) 78(11):5707-5719.
   PubMed Web of Science ®Google Scholar
• SCHUPPAN D, KREBS A, BAUER M, HAHN EG: Hepatitis C and liver fibrosis. Cell Death Differ. (2003) 10(s1):s59-s67.
   PubMed Web of Science ®Google Scholar
• VISVANATHAN K, LEWIN SR: Immunopathogenesis: role of innate and adaptive immune responses. Semin. Liver Dis. (2006) 26(2):104-115.
   PubMed Web of Science ®Google Scholar
• CASTILLA A, PRIETO J, FAUSTO N: Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N. Engl. J. Med. (1991) 324(14):933-940.
   PubMed Web of Science ®Google Scholar
• ANNONI G, WEINER FR, ZERN MA: Increased transforming growth factor-beta 1 gene expression in human liver disease. J. Hepatol. (1992) 14(2-3):259-264.
   PubMed Web of Science ®Google Scholar
• ROULOT D, SEVCSIK AM, COSTE T, STROSBERG AD, MARULLO S: Role of transforming growth factor beta Type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology (1999) 29(6):1730-1738.
   PubMed Web of Science ®Google Scholar
• KINNMAN N, GORIA O, WENDUM D et al.: Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab. Invest. (2001) 81(12):1709-1716.
   PubMed Web of Science ®Google Scholar
• THIMGAN MS, YEE HF JR: Quantitation of rat hepatic stellate cell contraction: stellate cells' contribution to sinusoidal resistance. Am. J. Physiol. (1999) 277(1 Pt 1):G137-143.
   PubMed Web of Science ®Google Scholar
• BOSCH J, GARCIA-PAGÀN JC: Complications of cirrhosis. Portal hypertension. J. Hepatol. (2000)32(1s):141-156.
   PubMed Web of Science ®Google Scholar
• ZHANG JX, BAUER M, CLEMENS MG: Vessel- and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver. Am. J. Physiol. (1995) 269(2 Pt 1):G269-G277.
   PubMed Web of Science ®Google Scholar
• ROCKEY DC, FOUASSIER L, CHUNG JJ et al.: Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology (1998)27(2):472-480.
   PubMed Web of Science ®Google Scholar
• MALLAT A, FOUASSIER L, PREAUX AM, MAVIER P, LOTERSZTAJN S: Antiproliferative effects of ET-1 in human liver Ito cells: an ETB- and a cyclic AMP-mediated pathway. J. Cardiovasc. Pharmacol. (1995) 26(s3):S132-S134.
   PubMed Web of Science ®Google Scholar
• MALLAT A, PREAUX AM, SERRADEIL-LE GAL C et al.: Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway. Inhibition of both extracellular signal-regulated kinase and c-Jun kinase and upregulation of endothelin B receptors. J. Clin. Invest. (1996) 98(12):2771-2778.
   PubMed Web of Science ®Google Scholar
• PINZANI M, MILANI S, DE FRANCO R et al.: Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology (1996) 110(2):534-548.
   PubMed Web of Science ®Google Scholar
• KAWADA N, TRAN-THI TA, KLEIN H, DECKER K: The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur. J. Biochem. (1993) 213(2):815-823.
   PubMedGoogle Scholar
• OIDE H, TATEYAMA M, WANG XE et al.: Activated stellate (Ito) cells possess voltage-activated calcium current. Biochim. Biophys. Acta (1999) 1418(1):158-164.
   PubMed Web of Science ®Google Scholar
• MELTON AC, DATTA A, YEE HF JR: [Ca2+]i-independent contractile force generation by rat hepatic stellate cells in response to endothelin-1. Am. J. Physiol. Gastrointest. Liver Physiol. (2006) 290(1):G7-G13.
   PubMed Web of Science ®Google Scholar
• ZHANG JX, PEGOLI W, CLEMENS MG: Endothelin-1 induces direct constriction of hepatic sinusoids. Am. J. Physiol. (1994) 266(4 Pt 1):G624-G632.
   PubMed Web of Science ®Google Scholar
• ROCKEY DC, WEISIGER RA: Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology (1996) 24(1):233-240.
   PubMed Web of Science ®Google Scholar
• BALLET F, CHRETIEN Y, REY C, POUPON R: Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J. Pharmacol. Exp. Ther. (1988) 244(1):283-289.
   PubMed Web of Science ®Google Scholar
• REINEHR R, FISCHER R, HAUSSINGER D: Regulation of endothelin-A receptor sensitivity by cyclic adenosine monophosphate in rat hepatic stellate cells. Hepatology (2002) 36(4 Pt 1):861-873.
   PubMed Web of Science ®Google Scholar
• KAWADA N, KLEIN H, DECKER K: Eicosanoid-mediated contractility of hepatic stellate cells. Biochem. J. (1992) 285(Pt 2):367-371.
   PubMed Web of Science ®Google Scholar
• HUI AY, CHENG AS, CHAN HL et al.: Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line. Prostaglandins Leukot. Essent. Fatty Acids (2004) 71(5):329-333.
   PubMed Web of Science ®Google Scholar
• MONCADA S, GRYGLEWSKI R, BUNTING S, VANE JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 263(5579):663-665.
   PubMed Web of Science ®Google Scholar
• ZARDI EM, ZARDI DM, CACCIAPAGLIA F et al.: Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogues. Int. Immunopharmacol. (2005) 5(3):437-459.
   PubMed Web of Science ®Google Scholar
• ZARDI EM, ZARDI DM, DOBRINA A, AFELTRA A: Prostacyclin in sepsis: a systematic review. Prostaglandins Other Lipid Mediat. (2007) 83(1-2):1-24.
   PubMed Web of Science ®Google Scholar
• GREENWEL P, DOMINGUEZ-ROSALES JA, MAVI G, RIVAS-ESTILLA AM, ROJKIND M: Hydrogen peroxide: a link between acetaldehyde-elicited alpha1 (I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology (2000) 31(1):109-116.
   PubMed Web of Science ®Google Scholar
• SVEGLIATI BARONI G, D’AMBROSIO L, FERRETTI G et al.: Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology (1998) 27(3):720-726.
   PubMed Web of Science ®Google Scholar
• OKBOY N, YEGEN C, AKTAN AO et al.: The effect of iloprost and NDGA in ischemia reperfusion injury in rat liver. Prostaglandins Leukot. Essent. Fatty Acids (1992) 47(4):291-295.
   PubMed Web of Science ®Google Scholar
• TANAKA J, MALCHESKY PS, OMOKAWA S et al.: Effects of prostaglandin I2, superoxide dismutase, and catalase on ischemia-reperfusioninjury in liver transplantation. ASAIO Trans. (1990) 36(3):M600-M603.
   PubMedGoogle Scholar
• KOHYAMA T, LIU X, KIM HJ et al.: Prostacyclin analogs inhibit fibroblast migration. Am. J. Physiol. Lung Cell. Mol. Physiol. (2002) 283(2):L428-L432.
   PubMed Web of Science ®Google Scholar
• JORRES A, DINTER H,TOPLEY N, GAHL GM, FREI U, SCHOLZ P: Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine (1997) 9(2):119-125.
   PubMed Web of Science ®Google Scholar
• EISENHUT T, SINHA B, GROTTRUP-WOLFERS E, SEMMLER J, SIESS W, ENDRES S: Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology (1993) 26(3):259-264.
   PubMedGoogle Scholar
• STRATTON R, SHIWEN X, MARTINI G et al.: Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J. Clin. Invest. (2001) 108(2):241-250.
   PubMed Web of Science ®Google Scholar
• ZARDI EM, PICARDI A, AMBROSINO G, SERIO A, COSTANTINO S, DOBRINA A: Hemodynamic effects of a PGI2 analogue (iloprost) on portal flow velocity and volume and visceral arteries circulation in patients with lower limb arteriopathy. Ultrasound Med. Biol. (2003) 29(2):209-213.
   PubMed Web of Science ®Google Scholar
• ZARDI EM, PICARDI A, AMBROSINO G et al.: Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis. In vivo (2006) 20(3):377-380.
   PubMed Web of Science ®Google Scholar
• KIEFER P, TUGTEKIN I, WIEDECK H et al.: Hepato-splanchnic metabolic effects of the stable prostacyclin analogue iloprost in patients with septic shock. Intensive Care Med. (2001) 27(7):1110-1112.
   PubMed Web of Science ®Google Scholar
• ZARDI EM, PICARDI A, FAZIO VM et al.: Improved hepatic perfusion after iloprost infusion in patients with HCV chronic infection. A pilot study with possible therapeutic implications. J. Interferon Cytokine Res. (2004) 24(5):297-300.
   PubMed Web of Science ®Google Scholar
• SALERA D, ARGALIA G, GIUSEPPETTI GM: Hemodynamic effects of a prostacyclin analog (Prostavasin) in systemic scleroderma patients. Radiol. Med. (Torino) 2005 110(1-2):106-114.
   PubMed Web of Science ®Google Scholar
• NEUMANN UP, KAISERS U, LANGREHR JM et al.: Reduction of reperfusion injury with prostacyclin I2 after liver transplantation. Transplant. Proc. (1999) 31(1-2):1029-1030.
   PubMed Web of Science ®Google Scholar
• NEUMANN UP, KAISERS U, LANGREHR JM et al.: Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial. Clin. Transplant. (2000) 14(1):70-74.
   PubMed Web of Science ®Google Scholar
• KLEIN M, GEOGHEGAN J, WANGEMANN R, BOCKLER D, SCHMIDT K,SCHEELE J: Preconditioning of donor livers with prostaglandin I2 before retrieval decreases hepatocellular ischemia-reperfusion injury. Transplantation (1999) 67(8):1128-1132.
   PubMed Web of Science ®Google Scholar
• NARUMIYA S, SUGIMOTO Y, USHIKUBI F: Prostanoid receptors: structures, properties, and functions. Physiol. Rev. (1999) 79(4):1193-1226.
   PubMed Web of Science ®Google Scholar
• WISE H, JONES RL: Focus on prostacyclin and its novel mimetics.Trends Pharmacol. Sci. (1996) 17(1):17-21.
   PubMed Web of Science ®Google Scholar
• STITHAM J, AREHART EJ, GLEIM SR, DOUVILLE KL, HWA J: Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediat. (2007) 82(1-4):95-108.
   PubMed Web of Science ®Google Scholar
• ZARDI EM, VESPASIANI GENTILUCCI U et al.: Iloprost: an adjunctive approach to chronic viral hepatitis treatment. Med. Hypotheses (2005) 64(1):46-52.
   PubMed Web of Science ®Google Scholar
• BURSCH W, TAPER HS, SOMER MP et al.: Histochemical and biochemical studies on the effect of the prostacyclin derivative iloprost on CCl4-induced lipid peroxidation in rat liver and its significance for hepatoprotection. Hepatology (1989) 9(6):830-838.
   PubMed Web of Science ®Google Scholar
• Divald A, Ujhelyi E, Jeney A, Lapis K, Institoris L: Hepatoprotective effects of prostacyclins on CCl4-induced liver injury in rats. Exp. Mol. Pathol. (1985) 42(2):163-166.
   PubMed Web of Science ®Google Scholar